Abstract 3359: Multiple objective analysis of first line medicine with non-small cell lung cancer

Yueh-Fu Fang, Min-Chia Lee
{"title":"Abstract 3359: Multiple objective analysis of first line medicine with non-small cell lung cancer","authors":"Yueh-Fu Fang, Min-Chia Lee","doi":"10.1158/1538-7445.SABCS18-3359","DOIUrl":null,"url":null,"abstract":"Background The standard first line treatments of lung cancer are chemotherapy and targeted therapy. Taiwan launch National Health Insurance since 1995 and Taiwanese can receive medical treatment in a low price. However, National Health Insurance facing bankruptcy so it is important to find which treatment provide good medical effect and low medical cost. We will use analytic hierarchy process (AHP) to combine medical effect and medical cost. Patients and Methods We had analyzed the Database of Lung Cancer from Taiwan National Health Insurance Database (NHIRD). The database included the coding of diagnoses, examinations and treatments from 1996 to 2013 in the patients who were diagnosed with lung cancer in 1996 to 2013. The Analytic Hierarchy Process (AHP) is a theory of measurement through pairwise comparisons. It relies on the judgements of experts to get the weight of the pairwise comparison. And it uses the pairwise comparison to derive priority scales. It scales that measure intangibles in relative terms. The methods of survival analysis are Kaplan-Meier method and Life table method. Results The aim of the questionnaire for AHP is to get the weights between each criteria or subcriteria. The weight of medical effect is about 71%, and the weight of medical cost is approximately 29%. According to the result of questionnaire, medical effect is much more important than medical cost. There are four part of medical cost. The weight is about 23% in average medical cost in first line. The weight is about 22% in average medical cost related to lung cancer in first line. The weight is approximately 26% in average medical cost per day after receiving first treatment. The weight is about 29% in average medical cost related to lung cancer per day after receiving first treatment. The average progression survival day is 106.86 days. The overall survival day is 262.68 days. The average time of the emergency is 2.15. The average medical cost in first line is 4655.38 new Taiwan dollars per day. The average medical cost related to lung cancer in first line is 4545.92 new Taiwan dollar per day. The average cost after receiving the first treatment is 3369.75 new Taiwan dollar per day. The average cost related to lung cancer after receiving first treatment is 3262.38 new Taiwan dollar. KPI of chemotherapy with Cisplatin or Carboplatin is higher than thatn of chemotherapy without Cisplatin or Carboplatin. For those who only use chemotherapy medicine, the highest KPI is not fixed on a certain medicine. In addition, Alimta is the most expensive one so that the lowest KPI is usually on Alimta. Conclusion This is the first time not only using the survival analysis but also using a new method to evaluate the efficiency of a treatment or drug. The future work is to develop a new method based on this analytic model. Citation Format: Yueh-Fu Fang, Min-Chia Lee. Multiple objective analysis of first line medicine with non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3359.","PeriodicalId":21579,"journal":{"name":"Science and Health Policy","volume":"229 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science and Health Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.SABCS18-3359","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background The standard first line treatments of lung cancer are chemotherapy and targeted therapy. Taiwan launch National Health Insurance since 1995 and Taiwanese can receive medical treatment in a low price. However, National Health Insurance facing bankruptcy so it is important to find which treatment provide good medical effect and low medical cost. We will use analytic hierarchy process (AHP) to combine medical effect and medical cost. Patients and Methods We had analyzed the Database of Lung Cancer from Taiwan National Health Insurance Database (NHIRD). The database included the coding of diagnoses, examinations and treatments from 1996 to 2013 in the patients who were diagnosed with lung cancer in 1996 to 2013. The Analytic Hierarchy Process (AHP) is a theory of measurement through pairwise comparisons. It relies on the judgements of experts to get the weight of the pairwise comparison. And it uses the pairwise comparison to derive priority scales. It scales that measure intangibles in relative terms. The methods of survival analysis are Kaplan-Meier method and Life table method. Results The aim of the questionnaire for AHP is to get the weights between each criteria or subcriteria. The weight of medical effect is about 71%, and the weight of medical cost is approximately 29%. According to the result of questionnaire, medical effect is much more important than medical cost. There are four part of medical cost. The weight is about 23% in average medical cost in first line. The weight is about 22% in average medical cost related to lung cancer in first line. The weight is approximately 26% in average medical cost per day after receiving first treatment. The weight is about 29% in average medical cost related to lung cancer per day after receiving first treatment. The average progression survival day is 106.86 days. The overall survival day is 262.68 days. The average time of the emergency is 2.15. The average medical cost in first line is 4655.38 new Taiwan dollars per day. The average medical cost related to lung cancer in first line is 4545.92 new Taiwan dollar per day. The average cost after receiving the first treatment is 3369.75 new Taiwan dollar per day. The average cost related to lung cancer after receiving first treatment is 3262.38 new Taiwan dollar. KPI of chemotherapy with Cisplatin or Carboplatin is higher than thatn of chemotherapy without Cisplatin or Carboplatin. For those who only use chemotherapy medicine, the highest KPI is not fixed on a certain medicine. In addition, Alimta is the most expensive one so that the lowest KPI is usually on Alimta. Conclusion This is the first time not only using the survival analysis but also using a new method to evaluate the efficiency of a treatment or drug. The future work is to develop a new method based on this analytic model. Citation Format: Yueh-Fu Fang, Min-Chia Lee. Multiple objective analysis of first line medicine with non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3359.
摘要3359:一线药物治疗非小细胞肺癌的多目标分析
背景肺癌的标准一线治疗是化疗和靶向治疗。台湾从1995年开始实行全民健康保险,台湾人可以以较低的价格接受医疗。然而,国民健康保险面临破产,因此寻找哪种治疗能提供良好的医疗效果和较低的医疗费用是很重要的。我们将运用层次分析法(AHP)结合医疗效果与医疗成本。患者与方法我们分析了台湾全民健康保险数据库(NHIRD)中的肺癌数据库。该数据库包括1996年至2013年诊断为肺癌的患者1996年至2013年的诊断、检查和治疗的编码。层次分析法(AHP)是一种通过两两比较进行测量的理论。它依靠专家的判断来获得两两比较的权重。它使用两两比较来得出优先级尺度。它是用相对价值来衡量无形资产的尺度。生存分析方法有Kaplan-Meier法和生命表法。结果层次分析法问卷的目的是得到各标准或子标准之间的权重。医疗效果的权重约为71%,医疗费用的权重约为29%。问卷调查结果显示,医疗效果远比医疗费用重要。医疗费用分为四部分。在一线平均医疗费用中占23%左右。在一线与肺癌相关的平均医疗费用中占22%左右。其重量约占首次治疗后每天平均医疗费用的26%。在接受首次治疗后的平均每日肺癌相关医疗费用中占比约为29%。平均进展生存日为106.86天。总生存日为262.68天。紧急事件发生的平均时间为2.15。一线居民每日平均医疗费用为新台币4655.38元。一线居民平均每日肺癌相关医疗费用为新台币4545.92元。接受第一次治疗后的平均费用为每天新台币3369.75元。肺癌首次治疗后的平均费用为新台币3262.38元。使用顺铂或卡铂化疗的KPI高于不使用顺铂或卡铂的化疗。对于只使用化疗药物的患者,最高KPI并不固定在某一种药物上。此外,Alimta是最昂贵的,因此最低的KPI通常在Alimta上。结论这是首次将生存分析作为评价治疗或药物疗效的新方法。今后的工作是在此分析模型的基础上开发一种新的方法。引文格式:方岳富,李敏嘉。一线药物治疗非小细胞肺癌的多客观分析[摘要]。摘自:2019年美国癌症研究协会年会论文集;2019年3月29日至4月3日;亚特兰大,乔治亚州。费城(PA): AACR;癌症杂志,2019;79(13增刊):摘要nr 3359。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信